HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT.

Abstract
Fifteen patients with advanced, cisplatin-refractory germ cell tumors (GCT) were treated with iproplatin (CHIP). No objective responses were noted in any of the patients treated. By restricting the entry criteria to heavily pre-treated patients, the identification of new active agents in phase II trials may be hindered. Alternative strategies for the investigation of new agents in patients with GCT should be considered, particularly when studying the efficacy and relative toxicity of platinum analogues.
AuthorsB A Murphy, R J Motzer, G J Bosl
JournalInvestigational new drugs (Invest New Drugs) Vol. 10 Issue 4 Pg. 327-30 (Nov 1992) ISSN: 0167-6997 [Print] United States
PMID1336770 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antineoplastic Agents
  • Organoplatinum Compounds
  • iproplatin
  • Cisplatin
Topics
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Cisplatin (therapeutic use)
  • Drug Resistance
  • Humans
  • Male
  • Neoplasms, Germ Cell and Embryonal (drug therapy)
  • Organoplatinum Compounds (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: